Jessica Maria Atrio, MD, has demonstrated that a safe but less-frequently prescribed birth control "mini-pill" is effective for women taking HIV medications. Study title: Effect of protease inhibitors on pharmacokinetics of oral norethindrone contraception in hiv+ women
Read the full story: http://sc-ctsi.org/index.php/news/sc-ctsi-supported-research-drives-global-health-policy#.Ut2b6WTTktU
Austin Transplantation Sciences is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Transplantation Sciences.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Transplantation Sciences. Austin Transplantation Sciences accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Transplantation Sciences.
Austin Transplantation Sciences strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Dr. Kurt Stevenson - An Overview of Antimicrobial UseJohn Blue
An Overview of Antimicrobial Use - Dr. Kurt Stevenson, The Ohio State University Medical Center, from the 2012 NIAA One Health Approach to Antimicrobial Resistance and Use Symposium, October 26-27, 2012, Columbus, OH, USA.
More presentations at:
http://www.trufflemedia.com/agmedia/conference/2012-one-health-to-approach-antimicrobial-resistance-and-use
The Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthrit...RemedyPublications
Tocilizumab (TCZ) has variously been approved in combination with Methotrexate for the
treatment of Rheumatoid Arthritis (RA) in adults. The objectives of this Non-Interventional Study
(NIS) were to assess the efficacy and safety of TCZ in routine clinical use.
Clinical response to TCZ was evaluated by collecting Disease Activity Score 28 (DAS28) and other
efficacy parameters. The number and type of Adverse Events (AEs) and concomitant medication
were documented. The median treatment duration was 52 weeks.
The efficacy and safety analyses included 590 patients, 97.8% of whom had been pretreated with
disease-modifying anti-rheumatic drugs. DAS28 scores were available for 484 patients, of whom
67.98% experienced disease remission and 83.06% low disease activity at any time during treatment.
AEs were reported for 21.02% of the patients, with 10% serious events.
The results confirm that TCZ is efficacious and well tolerated in routine use for the treatment of RA.
As the results of this NIS are in line with existing data, a reevaluation of the risk-benefit balance of
TCZ for the treatment of RA does not seem necessary.
Jessica Maria Atrio, MD, has demonstrated that a safe but less-frequently prescribed birth control "mini-pill" is effective for women taking HIV medications. Study title: Effect of protease inhibitors on pharmacokinetics of oral norethindrone contraception in hiv+ women
Read the full story: http://sc-ctsi.org/index.php/news/sc-ctsi-supported-research-drives-global-health-policy#.Ut2b6WTTktU
Austin Transplantation Sciences is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Transplantation Sciences.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Transplantation Sciences. Austin Transplantation Sciences accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Transplantation Sciences.
Austin Transplantation Sciences strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Dr. Kurt Stevenson - An Overview of Antimicrobial UseJohn Blue
An Overview of Antimicrobial Use - Dr. Kurt Stevenson, The Ohio State University Medical Center, from the 2012 NIAA One Health Approach to Antimicrobial Resistance and Use Symposium, October 26-27, 2012, Columbus, OH, USA.
More presentations at:
http://www.trufflemedia.com/agmedia/conference/2012-one-health-to-approach-antimicrobial-resistance-and-use
The Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthrit...RemedyPublications
Tocilizumab (TCZ) has variously been approved in combination with Methotrexate for the
treatment of Rheumatoid Arthritis (RA) in adults. The objectives of this Non-Interventional Study
(NIS) were to assess the efficacy and safety of TCZ in routine clinical use.
Clinical response to TCZ was evaluated by collecting Disease Activity Score 28 (DAS28) and other
efficacy parameters. The number and type of Adverse Events (AEs) and concomitant medication
were documented. The median treatment duration was 52 weeks.
The efficacy and safety analyses included 590 patients, 97.8% of whom had been pretreated with
disease-modifying anti-rheumatic drugs. DAS28 scores were available for 484 patients, of whom
67.98% experienced disease remission and 83.06% low disease activity at any time during treatment.
AEs were reported for 21.02% of the patients, with 10% serious events.
The results confirm that TCZ is efficacious and well tolerated in routine use for the treatment of RA.
As the results of this NIS are in line with existing data, a reevaluation of the risk-benefit balance of
TCZ for the treatment of RA does not seem necessary.
Trends in management of rheumatoid arthritis Dr.Neena Mehan
Rheumatoid Arthritis (RA) is an auto-immune disease in which body mistakenly considers some parts of its own system as pathogens and attacks them.
Local Treatment in Periodontal pocket Journal PresentationDr. B.V.Parvathy
It was a systematic review and network meta-analysis aimed to evaluate the efficacy of adjunctive locally delivered antimicrobials, compared to sub gingival instrumentation alone or plus a placebo, on changes in probing pocket depth (PPD) and clinical attachment level (CAL), in patients with residual pockets during supportive periodontal care.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
2. lower with the LD schedule, and in the percentage of pa-
tients who received previous tumor necrosis factor
(TNF) blockers being higher with the LD schedule [1].
It is well known that the lower the level of disease ac-
tivity, the higher is the percentage of success in terms of
low-disease activity (LDA) or disease remission (DR).
Moreover, the chance of obtaining LDA or DR is higher
for the first biologic than for the second or third biologic
[9]. Yet, in this study the delta of improvement was sig-
nificantly better in the CD cohort, even though the trend
suggested that, the longer the observation period, the
lower the difference between the two dosages. Overall
the main conclusion was that there was “evidence about
the lack of any striking difference and perhaps no clinic-
ally significant difference between two different doses of
rituximab used in clinical practice”.
The Authors recognize that the lack of radiographic
data do not allow us to definitely state that the doses are
similarly effective from all viewpoints. In fact, the
IMAGE trial [10] showed a lower effectiveness of the LD
using radiographic damage in the first 6 months, this be-
ing similar to the control of structural progression in the
second 6 months.
In the study of Chatzidyonisiou et al. improvements
were already present after 3 months, suggesting that a
tight control of the outcomes following a treat-to-target
strategy (major clinical assessment every 3 months) is
possible in real life at both dosages. Given that similar
results were seen after 3 months, as well as after
6 months, in a treat-to-target strategy the CD would
very likely offer much more certainty of a result.
In conclusion, this study shows that in active, long
standing RA with functional impairment, a LD sched-
ule of rituximab gives 6-month follow-up clinical re-
sults similar to those obtained with CD, but the data
have to be interpreted in the absence of radiographic
analysis. The lack of a long-term assessment makes
any possible choice in terms of clinical practice diffi-
cult because we have no idea when the LD schedule
would lead us to re-treat patients when compared to
the CD.
The most important message relies on the possible
pharmacoeconomic consequences. The real clue, not
proven by the data available here however, could be the
possible third choice, demonstrated to be realistic by
Mariette et al. [11]: first infusion with the CD schedule
and, in cases with good response (DR or LDA), the LD
schedule for the re-treatments. This would really allow
us to save a lot of money (Fig. 1).
Abbreviations
ACR, American College Rheumatology percentage of improvement; CD,
conventional dose; DR, disease remission; LD, low dose; LDA, low disease
activity; RA, rheumatoid arthritis.
Acknowledgements
Supported by the ASRALES foundation.
Authors’ contributions
GF conceived the study and wrote the paper. BT gave comments and
suggestions. EG gave comments, read the paper and made corrections.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
References
1. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Lund Hetland M, Tarp U, et al.
Effectiveness of two different doses of rituximab for the treatment of
rheumatoid arthritis in an international cohort: data from the CERERRA
collaboration. Arthritis Res Ther. 2016;18:50.
2. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P,
Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients
with rheumatoid arthritis. N Engl J Med. 2004;350:2572–81.
3. Isaacs JD, Cohen SB, Emery P, Tak PP, Lei JWG, Williams S, et al. Effect of
baseline rheumatoid factor and anticitrullinated peptide antibody serotype
on rituximab clinical response. Ann Rheum Dis. 2013;72:329–36.
4. Edwards JC, Cambridge J. Is rheumatoid arthritis a failure of B cell death in
synovium? Ann Rheum Dis. 1995;54:696–700.
5. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in
the treatment of autoimmune diseases. Immunobiol. 2002;206:519–27.
6. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak
PP. Early effects of rituximab on the synovial cell infiltrate in patients with
rheumatoid arthritis. Arthr Rheum. 2007;56:772–8.
Fig. 1 Rituximab in rheumatoid arthritis patients with moderate (a) or high (b) disease activity at baseline. A possible pragmatic approach
following a treat-to-target strategy in the real world. The low-dose (LD) schedule for rituximab is likely appropriate in those with moderate disease
activity at baseline, with the conventional dose (CD) in those with high disease activity at baseline. More data are needed on a flexible schedule
to be used according to the effective B-cell depletion
Ferraccioli et al. Arthritis Research & Therapy (2016) 18:126 Page 2 of 3
3. 7. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski
L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with
active rheumatoid arthritis despite methotrexate treatment. Arthr Rheum.
2006;54:1390–400.
8. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G,
et al. Efficacy and safety of various repeat treatment dosing regimens of
rituximab in patients with active rheumatoid arthritis: results of a phase III
randomized study (MIRROR). Rheumatology. 2010;49:1683–93.
9. Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, et al.
Effectiveness of rituximab for the treatment of rheumatoid arthritis in
patients with prior exposure to anti-TNF: results from the CORRONA registry.
J Rheumatol. 2015;42:1090–8.
10. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W,
et al. Inhibition of joint damage and improved clinical outcomes with
rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE
trial. Ann Rheum Dis. 2011;70:39–46.
11. Mariette X, Rouanet S, Sibilia J, Combe B, Le Loët X, Tebib J, et al. Evaluation
of low-dose rituximab for the retreatment of patients with active
rheumatoid arthritis: a non-inferiority randomised controlled. Ann Rheum
Dis. 2014;73:1508–14.
Ferraccioli et al. Arthritis Research & Therapy (2016) 18:126 Page 3 of 3